On December 4, Pfizer's oral innovative drug Leflunomide®(Common name: Ritlecitinib Tosylate Capsules) has been rapidly rolled out across China just over a month after its approval, bringing a new treatment option to Chinese adolescents aged 12 and above and adults with severe alopecia areata.1. Rejoove™, a drug developed by Pfizer with global synchronized clinical trials and registration, will officially launch through multiple online and offline channels to meet the clinical needs of different patients, accelerating access for more Chinese patients with alopecia areata.
Leflunomide®Chinese Medicine Box
Professor Zhang Jianzhong, Director of the Hair Group of the Chinese Medical Association's Dermatology and Venereology Branch and from Peking University People's Hospital, issued the first prescription and stated, "Alopecia areata is a psychosomatic disease, with immune abnormalities being the main cause, while anxiety, depression, and other factors also play a certain role in the onset of the disease."2The newly launched Ritlecitinib Tosylate has good efficacy,"Bring a new systemic JAK treatment solution to Chinese patients with alopecia areata, apart from traditional treatments, and also help patients strengthen their confidence in treatment and start standardized treatment."
Professor Zhang Jianzhong, Director of the Hair Group of the Chinese Medical Association's Dermatology and Venereology Branch, Peking University People's Hospital
Professor Zhang Xingqi from the First Affiliated Hospital of Sun Yat-sen University issued the first prescription for the patient and remarked, "The launch of Ritlecitinib Tosylate in China is a milestone in the treatment of severe alopecia areata. This new drug fills the treatment gap for adolescent patients aged 12 to 17 with severe alopecia areata in China who previously had no available treatment options."1"The approval and clinical use of new drugs in China signify the progress of our country’s pharmaceutical industry aligning with international standards, which is a significant benefit for both clinicians and patients."
Professor Zhang Xingqi from the First Affiliated Hospital of Sun Yat-sen University
Professor Fan Weixin from the First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) issued the first prescription for a patient and introduced, "Severe alopecia areata should be treated as early as possible; delaying treatment will only increase the difficulty of treatment. Ritlecitinib Tosylate is a systemic oral medication that suppresses abnormal immune responses and is a dual JAK3/TEC inhibitor, providing more optional treatment options in clinical practice."
Professor Weixin Fan from Jiangsu Provincial People's Hospital
Next, Pfizer®Will be launched simultaneously online and offline across the network, to achieve drug accessibility at the fastest speed and meet patients' treatment needs. As of today, Leflunomide®Successfully completed the first launch on JD Health, utilizing innovative acceleration to enhance the convenience and safety of patient medication. Additionally, the first prescription was issued at Yonghe Healthcare, leveraging its mature and professional hair healthcare service system to promote standardized diagnosis and treatment for alopecia areata, providing patients with more comprehensive services.Globally approved and launched simultaneously, benefiting patients with alopecia areata across China
Alopecia areata is an inflammatory autoimmune disease that typically occurs on the scalp but can also affect facial hair such as eyebrows, eyelashes, and beards, as well as body hair in other areas.4A survey conducted across six provinces in China revealed that the prevalence of alopecia areata in China is 0.27%, with approximately 4 million patients.5Nearly 18.1% of patients with alopecia areata were diagnosed before the age of 18.6。In the future, Pfizer will actively explore more innovative channels, integrating with major hospitals across China and internet hospital platforms. While promoting the application of innovative drugs in outpatient services and providing clinical doctors with new treatment options, Pfizer will also offer patients more convenient medication services, helping more patients regain confidence and embrace a new life.
This information should only be viewed at its original link location. Pfizer assumes no responsibility for content accessed through other means. Please scan the QR code above to obtain the package insert information.For Healthcare Professionals OnlyApproval Number: PP-LGF-CHN-0064References
1 China's National Medical Products Administration Approves the Marketing of Ritlecitinib Tosylate Capsules (2023). https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20231019161001181.html
2 Wei Wenguo, Zeng Sanwu. Latest Research Progress on the Pathogenesis of Alopecia Areata[J]. International Journal of Biomedical Engineering. 2021;44(2):5.
3 King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023 May 6;401(10387): 1518-1529.
4 Hair Group of Dermatology and Venereology Branch of Chinese Medical Association. Chinese Guidelines for the Diagnosis and Treatment of Alopecia Areata (2019) [ B ]. Journal of Clinical Dermatology. 2020,49(2). DOI:10.16761/j.cnki.1000-4963.2020.02.002.
5 Wang Tinglin, Shen Yiwei, Zhou Cheng, Wang Xiaoyan, Ding Xiaolan, & Tian Shan et al. (2010). Epidemiological Investigation of Alopecia Areata Prevalence in Six Provinces of Mainland China. Abstracts of the 16th National Congress of Dermatology and Venereology of the Chinese Medical Association.
6 Caldwell CC, Saikaly SK, Dellavalle RP, et al. Prevalence of pediatric alopecia areata among 572,617 dermatology patients. J Am Acad of Dermatol. 2017;77(5):980-981.
7 Pfizer Reviron® China Package Insert [Pharmacological Action]
Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
